Value of Surveillance Studies for Patients With Stage I to II Diffuse Large B-Cell Lymphoma in the Rituximab Era
- 1 May 2015
- journal article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 92 (1), 99-106
- https://doi.org/10.1016/j.ijrobp.2015.01.039
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell LymphomaJournal of Clinical Oncology, 2014
- Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano ClassificationJournal of Clinical Oncology, 2014
- Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non‐Hodgkin and Hodgkin lymphomaAmerican Journal of Hematology, 2014
- Limited role for surveillance PET–CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapyBritish Journal of Cancer, 2013
- Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab eraAmerican Journal of Hematology, 2013
- High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national databaseLeukemia & Lymphoma, 2012
- Risk-adapted FDG–PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapyAnnals of Oncology, 2010
- Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of LymphomaJournal of Clinical Oncology, 2009
- Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-treated patient populationAnnals of Oncology, 2006
- Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s diseaseAnnals of Oncology, 2003